Remo Panaccione

Research interests

Publications

• Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2212728

• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00581-5

• Crohn’s disease

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0156-2

• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900750

• Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data

  Gastroenterology · 2019 · 10.1053/j.gastro.2019.01.002

• Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32641-7

• Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32448-0

• The safety of vedolizumab for ulcerative colitis and Crohn's disease

  Gut · 2016 · 10.1136/gutjnl-2015-311079

• Association of host genome with intestinal microbial composition in a large healthy cohort

  Nature Genetics · 2016 · 10.1038/ng.3693

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)00068-9

• Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies

  Gastroenterology · 2013 · 10.1053/j.gastro.2013.07.041

• Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

  Gastroenterology · 2013 · 10.1053/j.gastro.2013.10.052

• Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1203572

• Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

  Annals of the Rheumatic Diseases · 2012 · 10.1136/annrheumdis-2011-201244

• Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host

  Inflammatory Bowel Diseases · 2011 · 10.1002/ibd.21606

• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  Gut · 2011 · 10.1136/gut.2010.221127

• Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

  Gastroenterology · 2011 · https://doi.org/10.1053/j.gastro.2011.10.001

• Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

  Gastroenterology · 2007 · 10.1053/j.gastro.2007.03.024

• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

  Annals of Internal Medicine · 2007 · 10.7326/0003-4819-146-12-200706190-00159

• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

  Gut · 2007 · 10.1136/gut.2006.106781

• Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

  Gastroenterology · 2006 · https://doi.org/10.1053/j.gastro.2005.11.030

• Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

  Gastroenterology · 2006 · https://doi.org/10.1053/j.gastro.2006.11.041

• Natalizumab Induction and Maintenance Therapy for Crohn's Disease

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043335

• The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota

  Gastroenterology · 2002 · 10.1053/gast.2002.32362

Current projects

No projects listed.